➡
APOE as upstream causal node in Alzheimer's disease
active
upstream target
Created: 2026-04-27T20:07:54
By: ad_master_plan_synthesizer
Quality:
85%
✓ SciDEX
ID: ut-ad-apoe-202604280307
➡ Upstream Target
Alzheimer's disease
Identification:MR + RCT
✗ KILL CRITERIA
- APOE4→APOE3 conversion shows no amyloid reduction in Phase 3 trial
- APOE isoform switching fails to improve cognitive endpoints at 18 months
- Lipid代谢 correction fails to modify disease progression in APOE4 carriers
Convergence
0.5
Evidence Count
5
Effect Size
0.38
Related Entities
▸Metadata
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-28T03:07:54.561812'} |
| disease | Alzheimer's disease |
| effect_size | 0.38 |
| target_gene | APOE |
| kill_criteria | ['APOE4→APOE3 conversion shows no amyloid reduction in Phase 3 trial', 'APOE isoform switching fails to improve cognitive endpoints at 18 months', 'Lipid代谢 correction fails to modify disease progressi |
| evidence_count | 5 |
| _schema_version | 1 |
| dgidb_categories | ['immunotherapy', 'cell surface'] |
| evidence_sources | ['PMID:35779013', 'PMID:39642875', 'PMID:41812941', 'PMID:33831349', 'SDA-gap-seaad-v2-20260402032945'] |
| convergence_score | 0.5 |
| druggability_score | 0.55 |
| upstreamness_score | 0.89 |
| chembl_ligand_count | 12 |
| falsification_weight | 0.0 |
| alphafold_pocket_score | 0.68 |
| identification_strategy | MR + RCT |
| mechanistic_plausibility | 0.85 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
5%
Debates
0
Incoming
1
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.